Clinical Trial of BMS-986504 in Recurrent GBM Patients

This is an open-label, multi-center, Phase 0/1 dose-escalation trial designed to enroll up to 12 total recurrent glioblastoma (rGBM) participants with confirmed MTAP loss/deletion in their archival or pretreatment biopsy tissue, who are scheduled for surgical resection. MTAP loss/deletion will be determined by next-generation sequencing (NGS). The trial will include a dose escalation design to evaluate the pharmacokinetics (PK) and safety and tolerability of BMS-986504 (MRTX1719). The trial will be composed of a Phase 0 component and an Expansion Phase 1 component. Participants with tumors demonstrating a positive PK response in the Phase 0 component of the study will be eligible to enroll into the the Phase 1 component that will include 21-day cycles of therapeutic dosing of BMS-986504.

NCT Number	NCT06883747
Lead Sponsor	Nader Sanai
Conditions	Glioblastoma WHO Grade IV
Enrollment	12 participants
Start Date	2025-04-28
Primary Completion	2026-09-28 (estimated)
Study Completion	2027-09-28 (estimated)
Updated on ClinicalTrials.gov	2026-06-25